By modulating the miR-134-5p/CREB axis, circDLGAP4 was shown to attenuate dopaminergic neuronal damage and reduce neurodegeneration, highlighting its potential as a therapeutic target for mitigating PD progression [44]. Here, CREB1 is linked to Parkinson disease.